{"entity":{"id":"gkl-006","kind":"drug","name":"GKL-006 Injection","aka":["GKL-006"],"tldr":"GKL-006 Injection is an experimental autologous iNKT cell therapy from Beijing Gene Key Life Technology, in phase 2 trials for unresectable hepatocellular carcinoma and advanced pancreatic ductal adenocarcinoma.","summary":"GKL-006 Injection (GKL-006) is an autologous iNKT cell therapy from Beijing Gene Key Life Technology. An iNKT (invariant natural killer T) cell therapy: the patient's own iNKT cells are collected, grown in the laboratory and infused back, per the registry. Its furthest stage is phase 2, for unresectable hepatocellular carcinoma and advanced pancreatic ductal adenocarcinoma. ClinicalTrials.gov registers it in 4 studies linked below. Registry only: NCT07209813 phase 2 recruiting (HCC, with TACE); NCT07777211 phase 1/2 active not recruiting (pancreatic, with nab-paclitaxel and gemcitabine); NCT07713290 phase 1 active not recruiting (HCC, with TACE); NCT07845266 phase 1 completed (HCC, with TACE). Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Beijing Gene Key Life Technology: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07845266"},{"label":"Beijing Gene Key Life Technology: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07209813"},{"label":"Beijing Gene Key Life Technology: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07777211"},{"label":"ClinicalTrials.gov: trials of GKL-006","url":"https://clinicaltrials.gov/search?intr=GKL-006"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc-advanced","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["beijing-gene-key-life-technology"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07209813","nct07777211","nct07713290","nct07845266"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"GKL-006","modality":"Autologous iNKT cell therapy","mechanism":"An iNKT (invariant natural killer T) cell therapy: the patient's own iNKT cells are collected, grown in the laboratory and infused back, per the registry.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/gkl-006/","neighbours":{"cancer":[{"id":"hcc-advanced","kind":"cancer","name":"Advanced hepatocellular carcinoma (BCLC C)","route":"/cancers/hcc-advanced/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"company":[{"id":"beijing-gene-key-life-technology","kind":"company","name":"Beijing Gene Key Life Technology","route":"/companies/beijing-gene-key-life-technology/"}],"trial":[{"id":"nct07713290","kind":"trial","name":"A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma","route":"/trials/nct07713290/"},{"id":"nct07777211","kind":"trial","name":"A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer","route":"/trials/nct07777211/"},{"id":"nct07845266","kind":"trial","name":"Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma","route":"/trials/nct07845266/"},{"id":"nct07209813","kind":"trial","name":"GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma","route":"/trials/nct07209813/"}]}}